ABSI (Absci Corporation) Stock | Pipeline, Insider Trades & Financials

May 7, 2026

Absci Corporation Unaudited Condensed Consolidated Balance Sheets March 31, December 31, (In thousands, except for share and per share data) 2026 2025 ASSETS Current assets Cash and cash equivalents $ 8,627 $ 20,025 Mark

Absci Corporation reported significant advancements in its clinical trials and pipeline during Q1 2026. The company successfully completed the dosing of its single ascending dose cohorts for the ABS-201 trial, which is targeting androgenetic alopecia, and has initiated dosing of the multiple ascending dose cohort. Financially, Absci faced challenges with a drop in revenue and an increased net loss compared to the previous year, although it believes its financial reserves will sustain operations through mid-2028. The addition of ABS-202 to its pipeline signifies the company’s commitment to expanding its therapeutic offerings.

May 6, 2026

▲ +6.1%on this newsshared move

The Pre-clinical Science Behind ABS-201 for Endometriosis

ABS-201, an AI-designed anti-PRLR antibody, has shown promising results in preclinical studies for treating endometriosis. The treatment significantly reduced both spontaneous and evoked pain in mice models while suppressing inflammatory cytokines associated with the disease. A Phase 2 clinical study is expected to begin in Q4 2026, indicating potential for a new therapeutic option.

Mar 24, 2026

Absci Corporation Consolidated Balance Sheets December 31, December 31, (In thousands, except for share and per share data) 2025 2024 ASSETS Current assets Cash and cash equivalents $ 20,025 $ 41,213 Restricted cash - 15

Absci Corporation reported its fourth quarter and full-year 2025 financial results, highlighting progress in its ABS-201 HEADLINE trial, which has successfully dosed its first three cohorts with favorable safety data. ABS-201 demonstrates potential in treating androgenetic alopecia and endometriosis, both areas with significant unmet medical needs. The company also appointed Dr. Ransi Somaratne as Chief Medical Officer to enhance its clinical strategy. Despite a net loss of $115.2 million for the year, Absci maintains a solid cash position to fund operations into mid-2028.

program. He leaves behind a legacy of innovation that will continue to guide our mission as we advance these potentially life-changing therapies through the clinic". About Absci Absci is advancing the future of drug disc

Absci Corporation has appointed Ransi Somaratne, M.D., FACC, MBA, as its new Chief Medical Officer to lead clinical development efforts. Somaratne, previously with Vertex Pharmaceuticals, brings extensive experience in biopharmaceuticals and will focus on advancing Absci's innovative AI-designed therapeutics pipeline. This transition comes as the company sees rapid progress in its programs, particularly the flagship ABS-201. Additionally, Chief Innovation Officer Andreas Busch will retire in March 2026 but will continue to support the company as co-chair of the Scientific Advisory Board.

ABS-201 Case Study

ABS-201 is a promising anti-prolactin receptor antibody currently in Phase 1 trials for endometriosis, with a Phase 2 initiation expected in Q4 2026. It aims to address the underlying pathogenesis of endometriosis, offering potential dual action on pain and lesion proliferation. Preclinical studies show strong efficacy and a favorable safety profile, positioning it as a potential best-in-class treatment.

Nov 12, 2025

Absci Corporation Unaudited Condensed Consolidated Balance Sheets September 30, December 31, (In thousands, except for share and per share data) 2025 2024 ASSETS Current assets Cash and cash equivalents $ 9,476 $ 41,213

Absci Corporation announced its financial and operational results for the third quarter of 2025, highlighting its strategic focus on the ABS-201 program for androgenetic alopecia and endometriosis. The company is on track to initiate a Phase 1 trial for ABS-201 in December 2025 and plans to expand its indications. Despite a reported net loss of $28.7 million and declining revenue, Absci maintains a strong cash position, sufficient to fund operations into the first half of 2028. The interim results for ABS-101 also indicated a favorable safety profile, with exploratory partnerships being considered.

Aug 12, 2025

Absci Corporation Unaudited Condensed Consolidated Balance Sheets June 30, December 31, (In thousands, except for share and per share data) 2025 2024 ASSETS Current assets Cash and cash equivalents $ 38,024 $ 41,213 Rest

Absci Corporation reported its financial and operating results for the second quarter of 2025, revealing strong execution and positive developments in clinical trials. The company successfully raised approximately $64 million, ensuring funding through the first half of 2028. Absci also expanded its collaboration with Almirall to include a second dermatological target. Despite a net loss increase and a decline in revenue compared to the previous year, the outlook for ongoing clinical trials remains optimistic with major milestones anticipated in the near future.

Jul 24, 2025

Absci Announces Proposed Public Offering of Common Stock VANCOUVER, WA

Absci Corporation has announced a proposed underwritten public offering of $50 million of its common stock, with an additional $7.5 million option for underwriters. The funds raised will support the advancement of internally developed programs and investments in its Integrated Drug Creation platform. The offering is contingent on market conditions and the final terms will be outlined in a prospectus supplement to be filed with the SEC. Absci utilizes generative AI to enhance drug creation processes.

May 13, 2025

Absci Corporation Unaudited Condensed Consolidated Balance Sheets March 31, December 31, (In thousands, except for share and per share data) 2025 2024 ASSETS Current assets Cash and cash equivalents $ 46,995 $ 41,213 Res

Absci Corporation has reported its first quarter financial results for 2025, highlighting significant progress in its pipeline. The company has initiated a first-in-human study for its ABS-101 antibody, with interim data expected later this year. Additionally, promising non-human primate study results for ABS-201 support its development as a treatment for androgenetic alopecia. Despite reporting a net loss of $26.3 million, Absci's financial status remains strong, with enough cash reserves to sustain operations into mid-2027.

Mar 21, 2025

ABS-201 Case Study: Potential best-in-class antibody targeting the prolactin receptor for the treatment of androgenic alopecia

Absci has initiated a Phase 1/2a clinical trial for ABS-201, an antibody targeting the prolactin receptor to treat androgenic alopecia (AGA). The trial aims to establish safety and tolerability, with interim data expected in H2 2026. ABS-201 demonstrates high potency and a favorable safety profile, potentially addressing a significant unmet need in AGA treatment.

Mar 18, 2025

Absci Corporation Condensed Consolidated Balance Sheets December 31, December 31, (In thousands, except for share and per share data) 2024 2023 ASSETS Current assets Cash and cash equivalents $ 41,213 $ 72,362 Restricted

Absci Corporation reported its financial and operational results for Q4 and the full year of 2024, showcasing advancements in its AI Integrated Drug Creation platform. Notable highlights include the collaboration with AMD resulting in a $20 million investment and the expected initiation of Phase 1 studies for ABS-101. However, the company reported a net loss of $29 million for the last quarter and a decrease in total revenue compared to the previous year. Despite the financial challenges, there are positive prospects for its key therapeutic candidates.

IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding

IgDesign is a novel deep learning method for antibody design that has been validated in vitro. It successfully designs heavy chain complementarity-determining regions (CDRs) for eight therapeutic antigens, demonstrating superior performance compared to traditional methods. The model's ability to create high-affinity antibody binders positions it as a significant advancement in drug development. Additionally, the open-sourcing of its code and datasets promotes further research and application.

Nov 12, 2024

▼ -15%on this news· ran to -34% by day 3

Development of ABS-101: A potential best-in-class anti-TL1A antibody for the treatment of IBD

The article discusses the development of ABS-101, an innovative anti-TL1A antibody aimed at treating inflammatory bowel disease (IBD). It highlights the use of generative AI in designing this biologic, which is intended to optimize therapeutic properties such as reduced immunogenicity. The potential applications extend beyond IBD to other inflammatory and fibrotic conditions.

Nov 12, 2024

▼ -15%on this news· ran to -34% by day 3shared move

Absci Corporation Unaudited Condensed Consolidated Balance Sheets September 30, December 31, (In thousands, except for share and per share data) 2024 2023 ASSETS Current assets Cash and cash equivalents $ 38,195 $ 72,362

Absci Corporation reported its third-quarter financial results for 2024, highlighting advances in its drug development programs and partnerships. The company successfully met a milestone with AstraZeneca regarding AI-designed antibody sequencing and formed a collaboration with Twist Bioscience for novel antibody development. Despite increased revenue of $1.7 million, Absci faced a greater net loss of $27.4 million compared to the same quarter last year. The company expects to have sufficient funds to support operations into 2027 while progressing multiple internal programs through the pipeline.

Aug 14, 2024

Absci Corporation Unaudited Condensed Consolidated Balance Sheets June 30, December 31, (In thousands, except for share and per share data) 2024 2023 ASSETS Current assets Cash and cash equivalents $ 42,936 $ 72,362 Rest

Absci Corporation reported its second quarter 2024 financial results, showcasing significant advancements in its drug development pipeline, particularly for ABS-101, which demonstrated a promising extended half-life in studies. The company has partnered with Memorial Sloan Kettering Cancer Center to co-develop up to six oncology therapeutics. While Absci anticipates moderate revenue due to a decline from the previous year, the financial outlook remains positive with sufficient cash reserves to continue operations through early 2027.

May 14, 2024

Absci Corporation Unaudited Condensed Consolidated Balance Sheets March 31, December 31, (In thousands, except for share and per share data) 2024 2023 ASSETS Current assets Cash and cash equivalents $ 58,831 $ 72,362 Res

Absci Corporation reported its financial results for Q1 2024, highlighting advancements in its internal and partnered drug programs. The company initiated IND-enabling studies for its anti-TL1A antibody, ABS-101, and continues to progress ABS-201 and ABS-301 in preclinical studies. Despite a decrease in revenue and a slight increase in net loss, Absci successfully raised $86.4 million through a public offering and anticipates sufficient cash reserves to fund operations through mid-2027. The ongoing development of their pipeline and collaborations suggests a focus on addressing unmet medical needs in various therapeutic areas.

May 1, 2024

IgDesign: Antibody inverse folding with in vitro validation

IgDesign™ represents a significant advancement in antibody design, being the first experimentally validated inverse folding model. It demonstrates the capability to create antibody binders for various therapeutic antigens with high success rates, often surpassing the affinities of existing reference antibodies. This innovation is poised to enhance drug development and therapeutic design processes.

May 1, 2024

▲ +9.5%on this newsshared move

Human anti-MAGEA Antibodies Derived from Tertiary Lymphoid Structures of Cancer Patients

The article discusses a novel reverse immunology platform that utilizes machine learning to reconstruct human antibodies from tertiary lymphoid structures (TLS) found in patient samples. This approach aims to leverage immune transcriptomics to develop antibodies directly from diseased tissues, particularly those showing exceptional outcomes in various diseases. The technology holds promise for advancements in treating cancer and other conditions.

Mar 21, 2024

Absci Corporation Condensed Consolidated Balance Sheets December 31, December 31, (In thousands, except for share and per share data) 2023 2022 ASSETS Current assets Cash and cash equivalents $ 72,362 $ 59,955 Restricted

Absci Corporation reported its financial and operational results for the fourth quarter and full year of 2023, highlighting a strong pipeline and significant collaborations. The company initiated IND-enabling studies for its promising ABS-101 antibody and entered a collaboration with AstraZeneca worth up to $247 million. Despite these advancements, Absci reported an increased net loss and a decline in revenue for the fourth quarter year-over-year. However, the recent public offering bolstered its financial position and funding prospects through mid-2027.

Dec 20, 2023

Availability of Other Information about Absci Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.a

Absci Corporation has announced a strategic partnership with PrecisionLife to jointly develop a pipeline of AI-enabled therapeutics aimed at addressing unmet medical needs in chronic diseases. The collaboration will leverage Absci's strengths in antibody design along with PrecisionLife's insights into disease biology to target specific patient populations. This partnership allows Absci to achieve its goal of signing ten new Active Programs in 2023. Both companies express optimism about accelerating drug development through this collaboration.

Dec 12, 2023

Evaluating Zero-Shot Scoring for In Vitro Antibody Binding Prediction with Experimental Validation

The article discusses the evaluation of zero-shot scoring methods for predicting in vitro antibody binding. It emphasizes the importance of experimental validation in this context. The submission history and access options for the paper are also mentioned, highlighting the collaborative nature of arXivLabs.

Dec 4, 2023

▲ +12.6%on this news· ran to +36% by day 3

well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update

Absci Corporation has announced a collaboration with AstraZeneca to develop an AI-designed antibody for oncology targets. The partnership will leverage Absci's AI antibody drug creation platform alongside AstraZeneca's oncology expertise, aiming to expedite the discovery process of potential cancer treatments. The agreement includes an upfront commitment, research funding, and milestone payments, enhancing the financial prospects for Absci. This collaboration follows Absci's recent advances in antibody design validated through their generative AI models.

Absci Corporation Unaudited Condensed Consolidated Balance Sheets September 30, December 31, (In thousands, except for share and per share data) 2023 2022 ASSETS Current assets Cash and cash equivalents $ 69,733 $ 59,955

Absci Corporation reported its financial and operating results for Q3 2023, highlighting a new partnership with Almirall aimed at developing AI-designed therapeutics for dermatological diseases. The company revealed its internal pipeline consisting of four wholly-owned drug assets, each poised to progress toward investigational new drug application by 2025. Despite a decrease in revenue compared to the previous year, Absci's net loss also improved. The company anticipates an increase in new active programs and cash generation from partnerships in the coming year.

Scaling Data and AI for Multioptimized Biologics

Absci is advancing the design of biologic therapeutics by integrating AI and high-throughput data to meet complex specifications like binding affinity and immunogenicity. Their process involves generating valuable experimental data and utilizing proprietary algorithms to create biologic variants. This approach is validated by expert teams, ensuring the efficacy of the designs.

Nov 3, 2023

▲ +7.6%on this newsshared move

Better Lead Optimization with AI

The article discusses advancements in antibody optimization through AI, specifically using deep contextual LLMs. These models can predict binding affinities of unseen antibody variants and provide insights for improving drug developability and immunogenicity. The technical poster offers detailed information on this innovative approach.

Nov 3, 2023

▲ +7.6%on this newsshared move

De Novo Antibodies Designed with AI

The article discusses a technical poster showcasing the use of generative AI in antibody design. This approach aims to improve the speed, quality, and controllability of developing functional antibodies compared to traditional methods. The poster highlights the advantages of using zero-shot generative AI for more effective antibody discovery.

Nov 3, 2023

▲ +7.6%on this newsshared move

Codon Optimization with Deep Learning Models

The article discusses advancements in codon optimization using deep learning models. It highlights the development of contextual language models that learn codon usage from natural protein coding sequences. This innovative approach aims to provide a more reliable method for optimizing gene expression across various industries, showcasing significant potential for improving protein expression levels.

Oct 24, 2023

ABSIConferences/Events

Absci at the Senate AI Forum

Absci's CEO Sean McClain spoke at the Senate AI Insights Forum, emphasizing the importance of AI in drug discovery and the need for high-quality biological data. He highlighted the potential risks of AI misuse and the necessity for nuanced regulations to foster innovation while ensuring safety. The forum aimed to discuss U.S. leadership in AI and its implications for healthcare.

Absci Corporation Unaudited Condensed Consolidated Balance Sheets June 30, December 31, (In thousands, except for share and per share data) 2023 2022 ASSETS Current assets Cash and cash equivalents $ 61,048 $ 59,955 Rest

Absci Corporation reported strong advancements in its second quarter 2023, including new partnerships aimed at drug discovery and development. The company announced collaborations with a Google Ventures-backed biotech and Caltech, backed by the Gates Foundation, to create innovative medicines and affordable HIV vaccinations. Financially, revenue rose significantly to $3.4 million compared to the previous year's $1.0 million, but the company also reported a net loss of $41.7 million, exacerbated by a goodwill impairment charge. Despite this, Absci anticipates further growth and continued cash management through its strategic initiatives.

Aug 11, 2023

Using generative AI to unlock HIV

A collaboration between Caltech and Absci, funded by the Gates Foundation, seeks to develop an innovative HIV therapeutic vaccination using generative AI. This project aims to target conserved regions of the virus, potentially providing a breakthrough in HIV treatment. Shaheed Abdulhaqq, an HIV researcher at Absci, emphasizes the project's unique approach and the challenges posed by HIV's rapid mutation.

Jun 6, 2023

About Absci Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential

Absci has appointed Frans van Houten, former CEO of Philips, to its Board of Directors. Van Houten's extensive background in healthcare and technology is anticipated to contribute significantly to Absci's growth and strategic objectives in generative AI drug creation. His leadership during Philips' transformation positions him well to guide Absci as it seeks to enhance drug discovery through AI technologies. This appointment follows the recent addition of other industry executives to the board, demonstrating Absci's commitment to building a robust leadership team.

May 15, 2023

Absci Corporation Unaudited Condensed Consolidated Balance Sheets March 31, December 31, (In thousands, except for share and per share data) 2023 2022 ASSETS Current assets Cash and cash equivalents $ 11,409 $ 59,955 Res

Absci Corporation announced its first quarter 2023 financial results, showcasing significant advancements in its generative AI drug creation platform. The company has entered new partnerships to expedite drug discovery for chronic inflammatory and oncological diseases and has achieved breakthroughs in designing therapeutic antibodies. However, despite the optimistic developments, Absci reported a net loss of $23.4 million and experienced a decrease in cash reserves compared to the end of 2022. The company anticipates further growth in its active program count throughout the year.

Mar 30, 2023

Absci Corporation Condensed Consolidated Balance Sheets December 31, December 31, (In thousands, except for share and per share data) 2022 2021 ASSETS Current assets Cash and cash equivalents $ 59,955 $ 252,569 Restricte

Absci Corporation reported its financial and operational results for the fourth quarter and full year 2022, highlighting its advancements in drug creation through generative AI. The company achieved ten new active programs, surpassing its guidance, and reported lower net losses compared to the previous year. However, it also saw an increase in overall net losses for the year and a significant decrease in its cash reserves. Expectations for 2023 include continued growth in active programs and a focus on effective investments and operations.

Nov 9, 2022

Absci Corporation Condensed Consolidated Balance Sheets (unaudited) September 30, December 31, (In thousands, except for share and per share data) 2022 2021 ASSETS Current assets Cash and cash equivalents $ 107,324 $ 252

Absci Reports Third Quarter 2022 Financial Results Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, November 9, 2022 - Absci Corporation (Nas

Availability of Other Information about Absci Investors and others should note that we routinely communicate with investors and the public using our website ( www.absci.com ) and our investor relations website ( investor

Absci Welcomes Meta Senior Executive to Board of Directors Technology veteran Dan Rabinovitsj provides expertise in collaborating with technology partners to catalyze innovation as Absci accelerates generative AI drug creation VANCOUVER, Wash. and NEW YORK. November 2, 2022 --

goal," "estimates," "expects," "progress," and "intends," or similar expressions. We intend these forward-looking statements, including statements regarding technology development efforts and the application of those eff

Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer Dr. Busch transitions from Absci's Board of Directors to Absci's Executive Leadership team With a proven track record advancing drugs from discovery to market, Dr. Busch brings world-class R

Absci Corporation Condensed Consolidated Balance Sheets (unaudited) June 30, December 31, (In thousands, except for share and per share data) 2022 2021 ASSETS Current assets Cash and cash equivalents $ 206,021 $ 252,569

Absci Reports Second Quarter 2022 Financial Results and Business Update Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 VANCOUVER, Wash. and NEW YORK, August 11, 2022 - Absci C

Absci Corporation Condensed Consolidated Balance Sheets (unaudited) March 31, December 31, (In thousands, except for share and per share data) 2022 2021 ASSETS Current assets Cash and cash equivalents $ 226,004 $ 252,569

Absci Reports First Quarter 2022 Financial and Operating Results VANCOUVER, Wash. May 11, 2022 - Absci Corporation (Nasdaq ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today report

Absci Corporation Consolidated Balance Sheets (unaudited) December 31, December 31, (In thousands, except for share and per share data) 2021 2020 ASSETS Current assets Cash and cash equivalents $ 252,569 $ 69,867 Restric

Absci Reports Full Year 2021 Financial and Operating Results VANCOUVER, Wash. March 22, 2022 - Absci Corporation (Nasdaq ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported

website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Absci Forward-Looking Statements Certain statements relating to Abs

Absci Announces Research Collaboration with Merck Collaboration to leverage Absci's Deep Learning-Enabled Drug Creation and Bionic Protein technologies VANCOUVER, Wash. January 7, 2022 - Absci Corporation (Nasdaq ABSI), the drug and target discovery company harnessing deep lear

Nov 9, 2021

▼ -21.1%on this news· ran to -38% by day 3

Absci Corporation Condensed Consolidated Balance Sheets (unaudited) September 30, December 31, (In thousands, except for share and per share data) 2021 2020 ASSETS Current assets Cash and cash equivalents $ 279,262 $ 69,

Absci Reports Third Quarter 2021 Financial and Operating Results VANCOUVER, Wash. November 9, 2021 - Absci Corporation (Nasdaq ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today re

Sep 7, 2021